Hepatitis B Virus Promotes Angiogenesis in Hepatocellular Carcinoma by Increasing m6A Modification of VEGFA mRNA via IGF2BP3
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Xiaoxin Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, School of Basic Medical Sciences, Fuzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Vascular Endothelial Growth Factor A, RNA-Binding Proteins, Liver Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: This study was supported by the grants from the National Natural Science Foundation of China (Grant Nos. U1905209 and 32100519) and the Joint Funds for the Inn….
Abstract (Originalsprache)
Angiogenesis plays a crucial role in the development of HBV‐related hepatocellular carcinoma (HCC). VEGFA is a key angiogenic factor, and while its transcriptional regulation by HBV has been extensively studied, its posttranscriptional regulation by HBV remains poorly understood. Building on our previous findings that delineated an RBM15/YTHDF2/IGF2BP3 regulatory axis in m6A‐mediated RNA metabolism in HCC, this study further explores the posttranscriptional regulation of VEGFA by HBV. By MeRIP‐qPCR and integrating MeRIP‐seq data, we discovered that HBV enhances m6A methylation of VEGFA mRNA. Comprehensive cellular and molecular biology experiments demonstrated that HBV induces the upregulation of IGF2BP3, which serves as a key “reader” that recognizes and stabilizes VEGFA mRNA in an m6A methylation‐dependent manner. This stabilization leads to elevated VEGFA expression, promoting enhanced cellular functions such as HUVEC migration and tube formation. Furthermore, in an HBV‐associated HCC xenograft model, IGF2BP3 knockdown resulted in decreased VEGFA expression and inhibited tumor growth. This study expands our understanding of HBV‐driven angiogenesis and identifies the IGF2BP3‐VEGFA axis as a potential therapeutic target for antiangiogenic strategies in HBV‐related HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, School of Basic Medical Sciences, Fuzhou, China.
- Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Förderung
- This study was supported by the grants from the National Natural Science Foundation of China (Grant Nos. U1905209 and 32100519) and the Joint Funds for the Inn…
Zitieren
APA
Xu, X., Zhang, Y., Wu, S., Wu, Y., Lin, X., Chen, K., & Lin, X. (2025). Hepatitis B Virus Promotes Angiogenesis in Hepatocellular Carcinoma by Increasing m6A Modification of VEGFA mRNA via IGF2BP3. Journal of Medical Virology. https://doi.org/10.1002/jmv.70356
Vancouver
Xu X, Zhang Y, Wu S, Wu Y, Lin X, Chen K, et al. Hepatitis B Virus Promotes Angiogenesis in Hepatocellular Carcinoma by Increasing m6A Modification of VEGFA mRNA via IGF2BP3. Journal of Medical Virology. 2025. doi:10.1002/jmv.70356
BibTeX
@article{Xu2025,
author = {Xu, Xiaoxin and Zhang, Yi and Wu, Shuxiang and Wu, Yuecheng and Lin, Xinjian and Chen, Kunqi and Lin, Xu},
title = {Hepatitis B Virus Promotes Angiogenesis in Hepatocellular Carcinoma by Increasing m6A Modification of VEGFA mRNA via IGF2BP3},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70356}
}
EUVIMED